PROCRIT® is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin >10 g/dL to ≤13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. PROCRIT® is not indicated for patients who are willing to donate autologous blood pre-operatively.
PROCRIT® has not been shown to improve quality of life, fatigue, or patient well-being.
PROCRIT® is not indicated for use:
Patient scheduled for elective, noncardiac, nonvascular surgery
*Other causes of anemia may include vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding, etc.
Hb=hemoglobin; U=units.
Weekly
Daily
Deep venous thrombosis prophylaxis is recommended during PROCRIT® therapy. Please see WARNINGS AND PRECAUTIONS, section 5.1, of the FULL PRESCRIBING INFORMATION to learn more.
PROCRIT® is contraindicated in patients with uncontrolled hypertension, pure red cell aplasia (PRCA) that begins after treatment with PROCRIT® or other erythropoietin protein drugs, or serious allergic reactions to PROCRIT®. PROCRIT® from multiple-dose vials contains benzyl alcohol and is contraindicated in neonates, infants, pregnant women, and lactating women.1 Please see the FULL PRESCRIBING INFORMATION to learn more.